(Reuters) - Allergan Plc's (>> Allergan, Inc.) Chief Executive Brent Saunders will be second in command at the world's largest drug maker, after he made the biggest bet of his career by selling his company for a record $160 billion to Pfizer Inc (>> Pfizer Inc.).
Saunders, 45, an intrepid deal maker, has a history of eventually leading companies that he had helped combine.
For a timeline on Saunders' career:
1995-1997: Co-founds Healthcare Compliance Association, a company that provides consultation for healthcare providers.
Serves as Chief Compliance Officer at Thomas Jefferson University Hospital until 1997.
1998-1999: Chief Compliance Officer at Coventry Health Care.
1999-2003: Heads PricewaterhouseCoopers LLC's compliance business advisory.
2003-2009: Joins Schering-Plough in 2003 and heads its Global Consumer Healthcare unit. Credited with turning the company around before its sale to Merck & Co (>> Merck & Co., Inc.) in 2009.
2010-2013: Helms Bausch+Lomb, his first job as CEO. Sells company for $8.4 billion to Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) (>> Valeant Pharmaceuticals Intl Inc).
2013-2014: Named CEO of Forest Laboratories Inc. Instrumental in a $25 billion bid from Actavis Plc within six months into the job.
July 2014-present - Replaces Paul Bisaro as Actavis CEO. Outbids Valeant Pharmaceuticals and buys Botox-maker Allergan.
After changing the company's name to Allergan earlier this year, Saunders sells generic drugmaking business to Israeli drugmaker Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited)
[Source: Saunders' LinkedIn profile, Reuters data and company press releases]
(Reporting by Vidya L Nathan in Bengaluru, Editing by Anil D'Silva)